Palbociclib is an oral medication classified as a CDK4/6 inhibitor. It is specifically designed to interfere with the cell cycle, thereby inhibiting the proliferation of cancer cells. By targeting cyclin-dependent kinases 4 and 6 (CDK4/6), palbociclib effectively slows down the division of cancer cells.
